9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
7
2
0
0
0
Last 30D
1
0
0
0
0
1M Ago
0
0
0
0
0
2M Ago
5
2
0
0
0
3M Ago
1
0
0
0
0
Analysts have recently evaluated CG Oncology and provided 12-month price targets. The average target is $68.33, accompanied by a high estimate of $75.00 and a low estimate of $50.00. This current average has decreased by 1.92% from the previous average price target of $69.67.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive CG Oncology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Charlie Yang
B of A Securities
Announces
Buy
$65.00
-
Andres Maldonado
HC Wainwright & Co.
Maintains
Buy
$75.00
$75.00
Corinne Johnson
Goldman Sachs
Raises
Buy
$50.00
$43.00
Corinne Johnson
Goldman Sachs
Announces
Buy
$50.00
-
Andres Maldonado
HC Wainwright & Co.
Maintains
Buy
$75.00
$75.00
Andres Maldonado
HC Wainwright & Co.
Maintains
Buy
$75.00
$75.00
Josh Schimmer
Cantor Fitzgerald
Maintains
Overweight
$75.00
$75.00
Josh Schimmer
Cantor Fitzgerald
Maintains
Overweight
$75.00
$75.00
Andres ...Full story available on Benzinga.com
Benzinga
